Our Clinical Trials
The CALABC-001 Phase 1 trial will evaluate safety, pharmacokinetics, and exploratory biomarker responses in 90 patients with early Alzheimer’s disease. The trial uses a 1:1:1 randomization to placebo, low-dose, and high-dose oral C-001. Biomarkers include plasma pTau217, Aβ42/40 ratios, GFAP, and NfL.
The planned follow-on Phase 2 trial (CALABC-002) will enroll 300 patients globally, assessing disease-modifying potential using validated cognitive endpoints such as iADRS, ADAS-Cog13, and CDR-SB.